Analysts expect Quince Therapeutics, Inc. to report revenue of 0.00 for Q4 24, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | - | - | - | - |
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Quince Therapeutics, Inc. to report earnings per share of -34.64 for Q4 25, against a range of -36.91 to -32.37. The most recent reported quarter, Q2 26, came in at -12.31, a 54.3% beat against the -26.92 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -26.00 | -56.00 | -68.00 | -68.00 | -50.00 | - | 73.48 | -12.31 | - | - | - | - | - | - | - | |||||||||||
| High Estimate | -31.05 | -32.58 | -45.36 | -47.61 | -43.56 | -32.37 | -24.99 | -24.75 | -3.77 | -4.13 | -2.94 | -1.98 | 4.60 | 3.17 | 6.99 | |||||||||||
| Low Estimate | -33.61 | -34.88 | -51.12 | -56.71 | -47.54 | -36.91 | -28.41 | -29.09 | -4.09 | -4.43 | -3.46 | -2.24 | 4.22 | 2.89 | 6.31 | |||||||||||
| Consensus Estimate | -32.33 | -33.73 | -48.24 | -52.16 | -45.55 | -34.64 | -26.70 | -26.92 | -3.93 | -4.28 | -3.20 | -2.11 | 4.41 | 3.03 | 6.65 |